Previous 10 | Next 10 |
SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...
Gainers: Air T (AIRT) +156%.FAT Brands (FAT) +85%.Addex Therapeutics (ADXN) +72%.Senseonics Holdings (SENS) +57%.SIFCO Industries (SIF) +45%.Gevo (GEVO) +44%.Neoleukin Therapeutics (NLTX) +42%.Avinger (AVGR) +41%.IZEA Worldwide (IZEA) +23%.Harvest Capital Credit (HCAP) +20%.Losers: Jagua...
Gainers: Avinger (AVGR) +71%, Neoleukin Therapeutics (NLTX) +33%, Ampio Pharmaceuticals (AMPE) +25%, Odonate Therapeutics (ODT) +14%, INmune Bio (INMB) +9%.Losers: Jaguar Health (JAGX) -29%, Ocugen (OCGN) -23%, Second Sight Medical Produc...
Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-protein design. Neoleukin is developing one clinical therapeutic, NL-201 which is a...
Neoleukin Therapeutics ([[NLTX]] +0.4%) has submitted an Investigational New Drug ((IND)) application with the FDA to initiate a Phase 1 study its lead immunotherapeutic candidate, NL-201. NL-201 is a computationally designed de novo protein that is a mimetic of natural cytokines IL...
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational ...
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...
SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...
- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation - SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical compan...
Neoleukin Therapeutics (NLTX): Q3 GAAP EPS of -$0.04 beats by $0.19.Cash and cash equivalents of $201.2MPress Release For further details see: Neoleukin Therapeutics EPS beats by $0.19
News, Short Squeeze, Breakout and More Instantly...
Neoleukin Therapeutics Inc. Company Name:
NLTX Stock Symbol:
NYSE Market:
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its B...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Neoleukin Therapeutics Inc. (NLTX) is expected to report $-0.8 for Q3 2023